

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
21 June 2007 (21.06.2007)

PCT

(10) International Publication Number
WO 2007/068284 A1

(51) International Patent Classification:
A61N 1/365 (2006.01) A61N 1/378 (2006.01)

(21) International Application Number:
PCT/EP2005/056700

(22) International Filing Date:
12 December 2005 (12.12.2005)

(25) Filing Language: English

(26) Publication Language: English

(71) Applicant (for all designated States except US): **SYNERGIO AG** [CH/CH]; Vordergasse 3, CH-8200 Schaffhausen (CH).

(72) Inventor; and

(75) Inventor/Applicant (for US only): **SOLEM, Jan Otto** [NO/CH]; Erlenwisenstrasse 25, CH-8234 Stetten (CH).

(74) Agent: **KRAHBICHLER, Erik**; Krahbichler Intellectual Property Advisors AB, Kungsgatan 6, 4th Floor, S-252 21 Helsingborg (SE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.


(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: INTRA CARDIAC DEVICE, SYSTEM AND METHODS



(57) Abstract: An intra cardiac device is disclosed. The device comprises means for transforming kinetic energy from heart tissue movement into electrical energy in use, from which electrical energy information in respect of heart function is obtainable. Furthermore, a system is disclosed, comprising one such intra cardiac device and at least one receiver, wherein the intra cardiac device comprises means of communication, through which said at least one device communicates with the receiver(s) wirelessly. In this way energy from heart movement provides self contained intra cardiac devices for conveniently monitoring or stimulating a patient's heart.

WO 2007/068284 A1

INTRA CARDIAC DEVICE, SYSTEM AND METHODS

Field of the Invention

The present invention refers to an intra cardiac
5 device and methods for heart function intervention, such as
monitoring and controlling of said heart function.

Background of the Invention

Congestive heart failure (CHF) is a condition where
10 the heart is not able to pump enough blood to supply the
body with energy and oxygen. There are multiple causes for
the heart to fail, such as ischemic heart disease caused by
clogged arteries, cardiomyopathy of unknown reasons or end
stage after congenital heart diseases or heart valve
15 diseases. With an increasing aging of the population today,
the problem of CHF is increasing and is now the most common
cause of heart disease mortality. According to the American
Heart Association 5 million people in the United States
experience CHF, increasing in number by half a million
20 every year. 1% of the population over 50 years of age or 5%
of the more than 75 years old are affected by the condition
of CHF. Worldwide the number of people suffering from CHD
is estimated around 20 million. Independent of what the
reason for CHD, the symptoms and the treatment are the
25 same. The failing pump function causes low blood pressure
and low cardiac output resulting in renal failure, and a
lower urine production causes fluid retention in the body.

A failing left ventricle of the heart causes the
blood to be stagnant in the lungs, causing slow flow and
30 high pressures in the blood stream of the lungs. As a
result thereof, fluid will be pressed from the blood
vessels into the lung tissue resulting in a decreased gas
exchange in the lungs, a condition that worsens the heart
condition.

35 A right heart failure on the other hand causes slow
flow and stagnation of blood in the vein system of the

body. As a result thereof, fluid is pressed from the small blood vessels, the capillaries, into the various organ tissues including the fatty tissue under the skin. This fluid retention causes for instance weight gain, swollen
5 organs and legs and shortness of breath.

The treatment of CHF is first of all a correction of the underlying causes such as valvular disease or coronary artery blocks. However, for the majority of patients this treatment is too late. Surgically, only heart
10 transplantation and implantation of mechanical heart assist devices are available. However, only 2-3000 heart transplants are made worldwide in the youngest population, due to lack of donor organs. Also, mechanical assist devices are still experimental. Therefore the majority of
15 the patients are left with symptomatic medical treatment. First of all fluid restriction and treatment with diuretics are used. Other drugs are Angiotensin-converting Enzyme (ACE) inhibitors, beta-blockers and digitalis. Most of CHF patients live for a long time before dying and are
20 readmitted again and again in order to adjust medication or get diuretics injected. Changes in the heart movements, the volumes and the pressures occur fast. The symptoms, however, appear slowly, resulting in treatment too late.

Previously, Medtronic Inc. has introduced the
25 Chronicle device, an implantable Hemodynamic Monitor. That system contains a Lithium battery and a computing element to be implanted under the skin, remote from the heart. Further, this unit has a lead with a pressure transducer that extends into the heart where it can measure intra
30 cardiac pressure, an indirect indicator when diagnosing a heart condition. The Chronicle unit is capable of using several algorithms to present curves and trends that can be detected in a receiver outside the body.

Savacor Inc. has developed the HeartPOD™, a very
35 similar product to the Chronicle device, the major

difference being that the transducer located at the tip of a lead is implanted in the atrial septum wall measuring the pressure in the left atrium. A handheld computer serves as a patient monitor receiving physiological signals from an
5 implant by wireless transmission. Savacor's technology is based on apparatus and methods as described in US 6,328,699.

US 6,328,699 discloses an apparatus for treating congestive heart failure in a patient. However, this
10 apparatus is provided with a pressure transducer lead that is permanently implanted in the left atrium of the patients heart. This pressure transducer lead is connected to an electrical circuitry for processing electrical signals. Thus, the apparatus according to US 6,328,699 has the
15 disadvantage of presenting a lead (or wire) inside the body (and inside the heart) of the patient, rendering the apparatus inferior in respect of a device in no need of such a lead, said device being fully implantable in the body of the patient. Moreover, the device according to US
20 6,328,699 receives energy from a battery, which renders it inferior inn comparison to a device in no need of a battery.

Remon Medical Technologies Inc. has introduced a device for non-invasive assessment of pulmonary artery
25 pressure. A pressure transducer is inserted into the pulmonary artery and fixed there. The pressure transducer is connected to an implanted remote device collecting data from the implanted transducer. Ultrasound energy is applied from outside the body in order to activate and energize the
30 device. Wireless communication to an external unit is also supported when the device is powered-up.

CardioMEMS Inc. on the other hand has developed a similar system that can measure pressure by means of an un-
powered, permanently implantable pressure sensor, which is
35 energized by means of high frequency radio waves from

outside the body. The pressure sensor is intended for measuring intrasac pressure during endovascular abdominal aortic aneurysm (AAA) repair.

Disturbances of the heart rhythm

5 Pacemakers (PM) are electronic devices to be implanted in a human body with the purpose to regulate the heart beat and the heart rhythm by means of electrical stimuli in patients that have lost the ability to regulate the heart rhythm, e.g. a heart block is such a condition. A
10 PM 36, e.g. shown in Fig. 2, is a hermetically sealed metal can 38 that contains a battery 40 and an electronic circuit. The PM can is implanted in the body under the skin at a remote site from the heart. The PM delivers electrical stimuli to the heart by means of an electrical lead 42, or
15 multiple electrical leads 42, extending from the PM can 38 in one end to a heart tissue and in the other end having an un-insulated electrode tip 44 or another form of transducer at tip 44, respectively.

Rune Elmqvist, a Swedish engineer designed the first
20 implantable PM, and Dr. Aake Senning implanted the device into the body of the patient Arne Larsson in 1958. The patient lived for 43 years after the first implant and had additionally 23 different PMs implanted during his lifetime. This first PM had a battery that was
25 rechargeable, the first non rechargeable PM was developed simultaneously by Dr. Greatbach in USA and was implanted for the first time in 1960. Today only non-rechargeable PMs are used. The PM industry today is among the most
30 PMs are produced yearly. Some modern PMs are able also to detect irregular, sometimes life-threatening irregularities in the heart rhythm, also known as arrhythmia. Over time, PMs were combined with a defibrillator, called an implantable cardioverter defibrillator (ICD), to correct
35 such arrhythmia by means of an electrical shock.

Generally, there are two main problems with PM treatment today, related to the leads and to the battery.

The leads are insulated cables, connected hermetically sealed to the electronic circuit in the PM can in one end and connected to the heart tissue with an un-
5 insulated end, the electrode tip, in the other end. The tip is made of material that facilitates in-growth in the heart tissue. The insulation is made of medical quality polymers, usually polyurethane and is made as thin as possible in
10 order to save space. The insulation must be absolutely impermeable. If not, electrical leak currents will occur and the PM will not function. The core of the lead, the electrically conducting part, is made of a metal that is a good electrical conductor. Since the heart is constantly
15 bending and twisting, the metal in the conductor has to be very tolerant to bending without fracturing, a fracture occurs frequently and stops the electron transfer and the PM does not function. Lead infection is another large problem. Furthermore, the leads are immersed in the blood
20 stream, a perfect environment for bacteria, and in contact with subcutaneous tissue, a common site for infections, especially from the PM can pocket. Bacteria easily migrate from the skin to subcutaneous tissue and into the blood stream along the leads. Finally lead tips often dislocate
25 from the heart tissue, losing contact to the heart cells, and thereby no electron transfer to the heart tissue is possible. Insulation defects, conductor fracture, infections, and tip dislocations are some of the PM related issues that result in recurrent surgical operations,
30 usually including additional leads being put in, since retrieval of previously implanted leads is very difficult if not impossible in many cases. Thus patients normally end up having many leads, most of them not in use. When more complex devices are used, like an ICD or a PM that
35 stimulates and detects at different sites in the heart

(e.g. atrium and ventricle) a system may consist of up to four leads at implant, each of them prone to the problems described above.

The battery

5 Different energy sources have been explored for batteries, inclusive nuclear. However, only Lithium (Li) batteries have proven to function well in PMs and today this energy source is exclusively used. Like all batteries the main problem is durability. The electrons will only
10 flow through a closed circuit, from the negative pole of a battery through the load, i.e. the body, back to the positive pole of a battery, and then through the battery (electrical current is described in the opposite direction). Electrons returning to the battery join with
15 Iodine and then with Lithium to Lithium-Iodine (LiI), which is not a good electron conductor. Buildup of LiI increases the internal resistance in a Li battery. Increasing internal resistance causes a decreasing battery voltage and finally the available voltage becomes insufficient to
20 stimulate the heart and the battery is useless. A Li battery will deliver at its beginning-of-life around 2.8 V and in the best case it will have a linear output for 5 years. From this time the internal resistance increases exponentially, and when the voltage comes down to close to
25 the heart stimulation threshold, the battery has to be replaced. A Li battery will normally contain 2 Ah (ampere-hours) of capacity, the drain is typically 25 microamperes, giving a battery a theoretical lifetime of 80 000 hours. In reality, however, they seldom last longer than 5 years.

30 As one may see, the main problems related to PM treatment are related to the battery and to the leads.

Several attempts have been made to solve these problems.

For instance, W.H. Ko, in US 03,456,134, as published
35 July 15, 1969, discloses a piezoelectric converter for

converting body motion to electrical energy for driving electrical implants, such as a PM. Ko found that this piezoelectric system may deliver enough energy to run a PM when driven at a mechanical pulse rate and with a motion
5 similar to the heart motion of an animal, upon which it was tested. However he did neither suggested to integrate a piezoelectric system in a PM itself nor to implant such a conversion device in a heart. As nearly 40 years have passed since the disclosure of Ko, and no commercially
10 available PMs using Kos principle have become available, it is regarded that the skilled person in the field of implanted devices does not regard that it is feasible to carry out Kos piezoelectric system with implantable devices.

15 US 6,654,638 discloses ultrasonically activated electrodes that generally use a piezoelectric energy converter to convert energy from an external energy source, e.g. an ultrasonic element. This energy is stored within the electrode. It is also mentioned that the electrodes may
20 use the contracting heart to produce energy by compressing or deflecting a piezoelectric element. However, the electrodes disclosed in US 6654638 are always controlled by an external device. That means pacing action is not possible by the electrode itself without the interaction
25 with an external control unit. Furthermore, also the piezoelectric element is integrated into the housing of the electrode, whereby the piezoelectric element uses valuable space of the housing's surface that no longer is available for use as an electrode surface.

30 Hence, there is a need for a device which alleviates or avoids problems such as, but not limited to, those mentioned above, and which device is fully implantable in the body, such as in the vicinity of, or inside, the heart, of a patient, which device may be used for instance for CHF
35 cases, but also in acute situations in the intensive care

unit for patients suffering from acute heart failure, for instance after large myocardial infarctions, after catheter based coronary artery operation or after cardiac surgery, which device is in no need of battery (or batteries) or
5 lead(s), which device may continuously monitor the heart function and may initiate early medical counter measures.

Summary of the Invention

Accordingly, the present invention preferably seeks
10 to mitigate, alleviate or eliminate one or more of the deficiencies in the art and disadvantages, such as the above-identified, but not limited to, singly or in any combination, and solves problems, such as the above-identified, but not limited to, by providing a device
15 according to the appended patent claims.

For this purpose an intra cardiac device of this kind according to claim 1, is characterized by means for transforming kinetic energy from heart muscle movement into electrical energy in use, from which electrical energy
20 information in respect of heart function is obtainable.

Advantageous features of the invention are defined in the dependent claims.

More specifically, according to a first aspect of the invention, an intra cardiac device for heart function
25 intervention is provided that comprises means for transforming kinetic energy from heart tissue movement into electrical energy in use, from which electrical energy information in respect of heart function is obtainable.

The means for transforming kinetic energy into
30 electrical energy may be a magnet, movable relative a coil.

The means for transforming kinetic energy into electrical energy may be a rotatable pendulum, communicating with a magnet, rotatable relative a coil.

The means for transforming kinetic energy into
35 electrical energy may be a piezo-electric energy converter.

The intra cardiac device may comprise an energy storage means, such as a capacitor, adapted to store the transformed electrical energy for use by the intra-cardiac device.

5 The intra cardiac device may comprise a wireless transmitter or transceiver.

The intra cardiac device may comprise fixation means, for attachment of said device in or at the heart, such as a stent, tines or hooks, or a screw.

10 The intra cardiac device may comprise elutionable steroids.

The intra cardiac device may be configured to provide device function related data, such as administrative data, programmed data like mode, cardiac stimulation pacing rate, defibrillation energy, power unit condition.

15 The information may be information in respect of heart function such as measured data like heart rate, heart movement amplitude, heart movement acceleration, electrical heart rate, electrical signal amplitude, or data related to previous cardiac events stored in the intra cardiac device.

20 The intra cardiac device may be an electrical cardiac stimulator device, such as an implantable pacemaker, a cardioverter defibrillator or a defibrillator.

25 The intra cardiac device may comprise at least one electronic circuit.

The electronic circuit may comprise pacing algorithms and/or defibrillating algorithms.

The intra cardiac device may comprise a positive and a negative electrode.

30 The positive and a negative electrode may be configured to obtain electrical heart signals.

The electrical energy may in use of the intra cardiac device be stored in an energy storage means, wherein the energy storage means may be configured to provide energy stored therein for cardiac stimulation via said positive

and negative electrode when electrical heart signals are not obtained via said positive and negative electrode.

The poles may be made of good electrically conducting material.

5 The poles may be made of copper or steel or a polymer.

At least one of said poles may be covered with porous material.

10 The porous material may be activated carbon, sintered platinum-iridium or sputtered titanium-nitride.

The heart tissue may be a heart muscle.

15 The intra cardiac device may be a leadless (no external lead as conventionally known) and batteryless self-contained intra cardiac monitoring and/or intra cardiac stimulating heart device capable of wireless communication with other intra cardiac or extracorporeal devices.

20 According to a second aspect of the invention, a system is provided. The system comprises at least one intra cardiac device according to the first aspect of the invention, and at least one receiver, wherein the at least one intra cardiac device comprises means of communication, through which said at least one device may communicate wirelessly with said at least one receiver.

25 The at least one receiver may be an extracorporeal receiver located outside a patients body in use of said system having said at least one intra cardiac device implanted therein.

30 The at least one receiver may be located in a mobile terminal such as a mobile telephone, a fix-net telephone, an intensive care monitor, a pacemaker, a defibrillator, an infusion pump, or a transceiver of a telemetry system.

35 The system may comprise a plurality of said intra cardiac devices and a first intra cardiac device of said plurality of intra cardiac devices may be configured to

communicate with a receiver located in a second intra cardiac device of said plurality of intra cardiac devices.

The intra cardiac device of the system may be configured to communicate information in respect of heart
5 function derived from electrical energy information originated during conversion from kinetic heart movement energy to electrical energy to the receiver.

The means of communication may be wireless communication selected from the group comprising of
10 wireless radio transmission including Bluetooth or ZigBee, and ultrasound communication, or combinations thereof.

The system may further comprise a delivery system for an intra cardiac device, wherein the delivery system comprises an intra cardiac device according to the first
15 aspect of the invention, an introducer sheath (78), a guide wire (76), a diagnostic catheter (102), and a delivery catheter (94).

According to another aspect of the invention, a method of communication between a first intra cardiac
20 device according to the first aspect of the invention and a receiver is provided. The method comprises transforming kinetic energy from heart tissue movement into electrical energy, deriving information obtained from said transformed electrical energy related to said heart movement, and
25 communicating said information to said receiver wirelessly.

The method may further comprise using said information to electrically instruct a second intra cardiac device.

The method may further comprise using said
30 information in an external data assembly equipment for monitoring said heart movement.

According to yet another aspect of the invention, a method for monitoring heart function is provided. The method comprises converting kinetic energy from heart
35 tissue movement to electrical energy, and using information

related to said electrical energy as an indicator of said heart function.

The method may further comprise wirelessly communicating said information related to the electrical
5 energy to a receiver for interpretation.

The receiver may be located in an external data assembly equipment outside of the patient body.

The external data assembly equipment may be a mobile terminal such as a mobile telephone, or a fix-net telephone
10 line, an intensive care monitor, an infusion pump or a transceiver of a telemetry system.

According to still another aspect of the invention, a method of treatment of heart blocks and arrhythmias is provided. The method comprises transforming kinetic energy
15 from heart tissue movement into electrical energy, and deriving information obtained from said transformed electrical energy related to said heart movement, by the use of at least one intra cardiac device according to a first aspect of the invention; and obtaining electrical
20 heart signals from said at least one intra cardiac device, and stimulating the heart electrically by at least one intra cardiac device with at least a part of the transformed electrical energy.

The first intra cardiac device may communicate with
25 at least a second intra cardiac device.

The first intra cardiac device may act as a master device and the at least second intra cardiac device may act as a slave device.

According to yet a further aspect of the invention, a
30 method of monitoring congestive heart failure is provided. The method comprises transforming kinetic energy from heart tissue movement into electrical energy by the use of at least one intra cardiac device according to a first aspect of the invention, deriving information obtained from said
35 transformed electrical energy related to said heart

movement, and communicating said information to a receiver wirelessly.

According to yet another aspect of the invention, a method for positioning a system comprising any of the intra cardiac devices according a first aspect of the invention is provided. The method comprises positioning said intra cardiac device in the right ventricle (RV), in the middle cardiac vein or in the coronary sinus, positioning a second intra cardiac device inside the LV from the aorta, in the lateral marginal veins, in the great cardiac vein or in the coronary sinus, and positioning a third intra cardiac device inside the wall of the right atrium or right atrium appendage, wherein each of these intra cardiac devices implemented as units in a system will communicate with each other.

The method may further comprise positioning a fourth intra cardiac device, implemented as a defibrillator, inside the RV, the marginal veins, the great cardiac vein 4, the coronary sinus 2 or in the middle cardiac vein 10, which fourth intra cardiac device also will communicate with said first, second, and/or third intra cardiac device.

The intra cardiac devices may be attached to the heart surface directly for optimizing positioning, according to the method.

25

Brief Description of the Drawings

These and other aspects, features and advantages of which the invention is capable of will be apparent and elucidated from the following description of embodiments of the present invention, reference being made to the accompanying drawings, in which

30 Fig. 1 is a schematic illustration showing a human heart;

Fig. 2 is a schematic illustration showing a pacemaker or prior art monitoring device 36 like a HeartPod

from Savacor Inc., a Chronicle system from Medtronic or a Pacemaker implanted at a patients shoulder area, remote from the heart. A lead for transportation of electrons runs from the implant can to the pressure transducer and back or
5 in the case of a pacemaker to the heart tissue where the electron transfer takes place from the lead tip. These devices have a battery in the can;

Fig. 3 is a schematic block diagram showing an intra cardiac device according to an embodiment of the present
10 invention, wherein the device is capable of communicating with an external communication unit, e.g. outside the patient, via an integrated communication unit;

Fig. 4 a) is a schematic illustration showing an intra cardiac device producing electricity by means of
15 induction;

Fig. 4 b) is a schematic illustration showing another intra cardiac device producing electricity by means of induction;

Fig. 5 a) is a schematic illustration showing tines as fixation means for an intra cardiac device;
20

Fig. 5 b) is a schematic illustration showing a screw as fixation means for an intra cardiac device;

Fig. 5 c) is a schematic illustration showing a stent as fixating means for an intra cardiac device, the stent
25 pushing the device against a vessel wall and still leaving the lumen open for sufficient flow;

Fig. 6 a) is a schematic illustration showing an intra cardiac device according to an embodiment of the invention implemented with fixation tines;

30 Fig. 6 b) is a schematic illustration showing an intra cardiac device according to an embodiment of the invention having a fixation screw;

Fig. 7 a) is a schematic illustration showing an intra cardiac device according to an embodiment of the

invention delivered and fixed in the anterior inter-ventricular vein;

Fig. 7 b) is a schematic illustration showing an intra cardiac device according to an embodiment of the invention delivered and fixed in the lateral marginal vein;

Fig. 7 c) is a schematic illustration showing an intra cardiac device according to an embodiment of the invention delivered and fixed in the middle cardiac vein;

Fig. 7 d) is a schematic illustration showing an intra cardiac device according to an embodiment of the invention delivered and fixed in the right ventricle;

Fig. 7 e) is a schematic illustration showing an intra cardiac device according to an embodiment of the invention delivered and fixed in the left ventricle;

Fig. 7 f) is a schematic illustration showing an intra cardiac device according to an embodiment of the invention delivered and fixed on the heart surface;

Fig. 8 is a schematic block diagram of showing an intra cardiac device according to an embodiment of the invention having an energy unit powering a cardiac stimulator in the form of a pacemaker;

Fig. 9 is a schematic illustration showing a complete pacemaker system implemented with four intra cardiac device according to embodiments of the invention implemented as pacemaker units are implanted in the lateral marginal vein, the middle cardiac vein, in the right ventricle and in the right atrium appendage, respectively, and a further intra cardiac device according to an embodiment of the invention implemented as a defibrillation unit is located in the great cardiac vein, wherein the devices may communicate with each other and outside the patient by means of the built in communication units;

Fig. 10 a) is a schematic illustration showing access to the vein system through the internal Jugular vein;

Fig. 10 b) is a schematic illustration showing access to the vein system through the femoral vein;

Fig. 10 c) is a schematic illustration showing access to the left ventricle through the femoral artery;

5 Fig. 11 is are schematic illustrations showing a delivery system for fixation with tines and a screw respectively;

Fig. 12 is a schematic illustration showing a delivery system for fixation with stent;

10 Fig. 13 is a schematic illustration showing the insertion of a guide wire into the coronary sinus through the internal Jugular vein;

Fig. 14 a) is a schematic illustration showing a guide wire and a guiding catheter introduced through the coronary sinus, the great cardiac vein and into the anterior inter-ventricular vein;

15 Fig. 14 b) is a schematic illustration showing an intra cardiac device according to an embodiment of the invention delivered in the great cardiac vein by means of a stent; and

20 Fig. 15 is a schematic illustration showing a complete heart function monitoring system according to an embodiment of the invention with an external communication unit.

25

Embodiments of the Invention

The following description focuses on embodiments of the present invention applicable to a device, and in particular to a method of using said device, for transforming kinetic energy of a heart 1 into electrical energy. The device may transmit data outside the body. However, it will be appreciated that the invention is not limited to this application but may be applied to many other embodiments.

It will be understood that the Figures are merely schematic and are not drawn to scale. For clarity of illustration, certain dimensions may have been exaggerated while other dimensions may have been reduced. Also, where
5 appropriate, the same reference numerals and letters are used throughout the Figures to indicate the same parts and dimensions.

In one embodiment the device according to the present invention is an intra cardiac device for heart function
10 intervention. This device has the capability to transform kinetic energy obtained from heart muscle movement into electrical energy in use. This electrical energy may then be used to obtain information in respect of heart function.

The term "intervention" is, in this context, meant to
15 be interpreted as monitoring, modifying, surveying, and/or controlling heart function and action.

In one embodiment of the present invention the herein presented device is designed to be implanted totally in the heart itself. Since the heart is constantly moving
20 vigorously in all three dimensions, a device provided in the heart has a certain potential kinetic energy. With modern technology, e.g. micro mechanical systems, such kinetic energy may be detected and transformed into electrical energy. Since the heart never stops, it is not
25 necessary to save any energy in batteries, if necessary possibly only momentarily in a capacitor. The electrical drain of 25 microamperes according to the prior art mentioned above includes the energy loss in the lead, thus the energy needed in a leadless system is much lower than
30 that with a lead.

Modern technology permits new solutions for transforming kinetic energy into electrical energy by means of Micro Electro Mechanical Systems, also called MEMS. These new solutions may be implemented in respect of the
35 embodiments according to the present invention. There are

different methods to transform kinetic energy into electrical energy, by using an energy conversion unit 5.

Electrical energy may be obtained by means of unit 5 by inductive conversion from kinetic energy. In this case, a magnet 52 is moving relative a coil 50, whereupon a voltage and current is generated in the coil 50. Magnet 52 for instance may be connected via a connection means such as a rod 48 and a gearbox to a pendulum 46 for converting heart tissue movements in three dimensions to a suitable movement of the magnet 52 relative coil 50. This may be achieved by moving a magnet 52 back and forth through the coil 50, as suggested by Lee et al 2003, in "AA Size micro Resonators". Lee demonstrated that up to 830 microwatts could be achieved with such a conversion device.

Therefore, in one embodiment of the present invention, electrical energy is achieved by moving a magnet 52 back and forth relative a coil 50.

Another energy conversion solution is to transform movements of a magnetic pendulum 46 in another embodiment of energy conversion unit 5 into rotation and then have the magnet 52 to rotate in the coil 50. The Seiko watch, a self winding electric watch, is an example that may produce up to 1 mW. A spring like in a self winding wrist-watch and a gear system might accelerate the rotational speed to 15000 rev/min, an optimal rate. Kula and Najafi could achieve 2.5 microwatt at 10 Hz in a MEMS. Hence, a pendulum of 2 g is sufficient to convert enough energy to supply a pacemaker, such as a pacemaker unit 70. In this respect, one embodiment of the present invention transforms movements of a magnetic pendulum 46 into rotation, and then have the magnet to rotate in a coil 50 to obtain electrical energy.

Piezo-electrical materials may produce an electrical current with no mechanical parts moving. Pressure on a piezo-electrical material produces a voltage. Roundy, 2003, produced 0.2 mW on a 1cm cube @ 120 Hz. Capacitive or

electrostatic methods might also be used . The housing of the intra cardiac device may comprise piezo electric elements for the energy conversion. However, in this case a part of the housing area is blocked for other use, e.g. as
5 electrode surface. As the intra cardiac device is very compact, housing surface is rather limited. Moreover, the housing itself has to be exposed to a pressure from the moving heart tissue. When the device is attached to the tissue, this is difficult to implement. Therefore, it is
10 proposed to have a piezo electric conversion means inside the housing, which is exposed to a mechanical pressure when the heart tissue accelerates. For instance, a T-bar like element which generates a lever on a piezo electric element due to resulting inertia of a lever perpendicularly
15 arranged to the piezo element may be used for piezo electric energy conversion. Accordingly, some embodiments of the invention are implemented by using piezo-electrical, capacitive or electrostatic energy conversion methods in embodiments of energy conversion unit 5.

20 Hence, a self-contained implantable intra cardiac device may be provided according to some embodiments.

The device according to some embodiments of the present invention provides the possibility to continuously monitor the heart function and initiate early intervention,
25 if the heart condition of a patient is deteriorating. An energy device fully implantable monitors in use the kinetic energy of a heart 1 and continuously transmit a report of the condition of the heart 1 to a receiver outside the body or to another device inside the body, for instance a
30 pacemaker, such as a pacemaker unit 70, a defibrillator or an infusion pump able to adjust the amount of diuretics to be injected. For this purpose, energy conversion unit 5 is via communication element 9, e.g. by wires or wirelessly, connected to a communication unit 7 inside a housing 11 of
35 the intra cardiac device 3, as shown in Fig. 3.

According to a specific embodiment, the device is self-contained and does not communicate with an extracorporeal device. The device according to this embodiment continuously monitors the heart function and
5 initiate early intervention, if the heart condition of a patient is deteriorating. The device is in use fully implanted in the heart 1 and converts kinetic energy from heart movements into electric energy. The conversion signal provides information to monitor the kinetic energy of the
10 heart 1 and continuously analyzes this information in order to activate a pacing circuitry if required.

A device according to one embodiment of the present invention may also be used in acute situations in the intensive care unit for patients suffering from acute heart
15 failure, for instance after large myocardial infarctions, after catheter based coronary artery intervention or after cardiac surgery. By means of the device according to the embodiment of the present invention, the kinetic energy of the heart 1 is transformed into electricity; the amount of
20 electrical energy achieved is related to the force of movement of the heart 1, an indicator of the heart condition. More specifically, an electrical signal is obtained when converting the heart movement kinetic energy into electrical energy. The electrical signal has a
25 characteristic electrical voltage and current over time. For instance, the maximum amplitude of the electrical signal may deliver information how fast the heart 1 is accelerating. The curve form may give information how the muscle exactly is accelerating, etc. Furthermore, no energy
30 is transferred to the herein presented inventive device from outside the heart 1.

In respect of the PM's according to the prior art, the herein presented device, according to some embodiments of the present invention, eliminates among others the
35 problems related to batteries and leads, since there is no

battery and there are no leads comprised in the herein presented PM.

In a first embodiment an energy unit is utilizing induction for creating electricity electromagnetic, by transforming the kinetic energy of the heart movements. This is achieved either by moving a magnet back and forth relative a coil 50, e.g. through the coil 50, or by rotating a magnet 52 relative a coil 50, e.g. by rotating a magnet 52 in a coil 50 or by rotating a coil 50 around a magnet 52, e.g. by means of a pendulum effect.

In a second embodiment electric current unit is utilizing a piezo-electric material, i.e. a material that creates an electric current when deformed.

In still another embodiment an energy unit is created utilizing electrostatic or capacitive technology.

The amount of electricity produced is an indicator of the kinetic energy of the heart 1 reflecting acceleration and movement of the site where the device is implanted. Acceleration and movements are indicators of the heart muscle condition at a given time. According to some embodiments, the device has a transmitter emitting a signal to a receiver, e.g. outside the body. Thus, the device according to some embodiments comprises an energy unit, an electronic control unit, a transmitting unit and fixation means. Some embodiments of the device may also comprise a transmitting and receiving unit (also called transceiver unit) instead of only a transmitting unit.

The receiver may also be incorporated in another device according to another embodiment of the invention. Thus, one implanted device may communicate with another implanted device, e.g. to give the other implanted device instructions in respect of when and how to act. For instance, a first implanted device may convert kinetic energy, analyze heart condition, and send a signal to a second implanted device if a heart failure is detected. The

second device also converts kinetic energy for powering a receiver and a pacing circuit. When the second implanted device receives a signal from the first implanted device, e.g. that pacing is necessary, the second implanted device
5 takes appropriate action.

In one embodiment wireless communication is provided by means of radio frequency (RF) transmission which may be digitally coded.

In one embodiment the means of communication is
10 provided by so called Bluetooth technology.

The new ZigBee technology might also be used in other embodiments. ZigBee is a published specification set of high level communication protocols designed to use small, low power digital radios based on the IEEE 802.15.4
15 standard for wireless personal area networks (WPANs). The technology is designed to be simpler and cheaper than other WPANs such as Bluetooth. The most capable ZigBee node type is said to require only about 10% of the software of a typical Bluetooth or Wireless Internet node, while the
20 simplest nodes are about 2%. ZigBee provides an inexpensive self-organizing mesh network. However, it has not yet been envisaged for use in implanted medical devices. ZigBee is designed to use very small amounts of power. This makes ZigBee perfectly suited for use in the implantable cardiac
25 devices of the present invention.

In still another embodiment ultrasound may be used for wireless communication with the intra cardiac device(s).

The data retrieved outside may be exact numeric data
30 of a current status or may also only comprise trends.

In another embodiment a device and a method for treatment of heart blocks and arrhythmias by means of an electrical cardiac stimulator without battery and leads are presented. The device is designed to be completely
35 implanted in a heart 1 or on a heart surface. In this

embodiment the device comprises five main components: an energy unit, an electronic control circuit, an electric contact surface towards the heart tissue, a communication unit 7 and finally means for attachment or fixation in or
5 to the heart 1.

In one embodiment of the intra cardiac device according to the present invention in the form of an electrical cardiac stimulator, an energy unit is utilizing induction for creating electricity by means of electro-
10 magnetically converting kinetic energy from heart movement into electrical energy. This is achieved either by moving a magnet 52 back and forth relative a coil 50 or by rotating a magnet 52 relative a coil 50, e.g. by rotating a magnet 52 in a coil 50 or by rotating a coil 50 around a magnet
15 52, e.g. by means of a pendulum effect.

In another embodiment of the electrical cardiac stimulator according to the present invention, an energy conversion unit is utilizing piezo-electric material, a material that creates an electric current when deformed.

20 In still another embodiment of the electrical cardiac stimulator according to an embodiment of the present invention, an energy conversion unit is based on electrostatic or capacitive conversion technology.

According to one embodiment, the electrical cardiac
25 stimulator's electronic circuit utilizes traditional PM algorithms on an electronic chip. The chip may for instance be of rectangular or square surface area, and by estimation the complete area is with current technology less than approximately one square centimeter in size. Further
30 miniaturization is envisaged with emerging technologies. The device has two electrode contact surfaces, preferably one at each end of the implant, one positive pole receiving the electrons and one negative emitting electrons into the heart tissue. The electrode contact surfaces are made of
35 good electrically conducting metal material like copper or

steel or other alloys. They may be covered with porous material like activated carbon, sintered platinum-iridium or sputtered titanium-nitride. The current is concentrated in a small area of contact with the myocytes by means of
5 designing the geometrical surface area of contact of the electrodes as small as is optimal. The surface may also be eluting steroids like dexamethasone from the surface initially in order to limit inflammation during healing in. The electrical cardiac stimulator device has a unit of
10 communication. The communication unit 7 may communicate with communication units in other devices implanted in the same heart 1, e.g. one in an atrium and one in a ventricle, or one electrical cardiac stimulator in the implementation of a PM unit and one electrical cardiac stimulator in the
15 implementation of an ICD unit. Thus, one unit may serve as a master and the others are slaved to the master. Thus, one device may communicate with another device, e.g. to give the other device instructions in respect of when and how to act. The communication unit 7 may also be designed to
20 communicate outside of the patient. Communication may occur one-way out of the device in order to deliver information from the implanted device (in this case the device has a transmitter only), or two-way so that the implanted device also may receive information (in this case the device has a
25 transceiver). In either case information that is transmitted may comprise information related to follow up of the device's function and for adjustments of it's mode of operation, for instance administrative data, programmed data like mode, rate etc., measured data like heart rate, mechanical cardiac function values, like local acceleration
30 at the implanted devices location, or the electrical pulse rate, electrical pulse amplitude, power unit condition etc., or stored data. The means of communication is based on wireless transmission technologies. In one embodiment
35 the means of communication is by means of radio frequency

(RF) waves. Communication may be digitally coded and/or authenticated in order to provide a secure and reliable data transmission to and/or from implanted device(s).

In another embodiment of the electrical cardiac stimulator device according to the present invention the means of communication is based on so called BluetoothTM technology. The new ZigBee technology may also be used in respect of the presently described electrical cardiac stimulators.

In still another embodiment of the electrical cardiac stimulator device according to the present invention ultrasound transmissions through the body may be used for wireless communication to/from the implanted device(s).

Again Nanotechnology and MEMS may be utilized for minimizing the communication unit 7 in the device.

In yet another embodiment the intra cardiac device according to the present invention is a congestive heart failure monitoring device 3. The congestive heart failure monitoring device 3 is intended to be inserted and fixated adjacent to the left ventricle of the heart 1. Preferably the device is inserted in the vein system through the coronary sinus 2 and the great cardiac vein 4 into smaller branches along the lateral wall of the left ventricular wall 26. Other positions in the vein system are in the anterior inter-ventricular vein on the front of the heart 1 or in the middle cardiac vein 10 behind the heart 1 between the left and the right ventricle, or in the great cardiac vein 4. In cases of right heart failure separately, the device is placed close to the right ventricle, in case only one embodied device is implanted.

In the Figures, e.g. Fig. 1, furthermore the following elements are illustrated for a better understanding of the present invention: anterior inter-ventricular vein 8, left atrium appendage 14, pulmonary artery 16, superior vena cava (SVC) 20, right ventricular

wall 24, tricuspid valve 32, mitral valve 34, right atrium appendage cavity 74, the femoral artery 84, the iliac artery 86, the aorta 88 and the inferior vena cava (IVC) 90.

5 The positioning of electrical cardiac stimulator devices, such as pacemaker (PM) devices, for example a pacemaker unit 70, according to embodiments of the present invention may also be more diverse or distributed over the heart 1, depending on the function of the different
10 components of a electrical cardiac stimulator system. For instance a first intra cardiac device implemented as a PM for stimulation of the right ventricle (RV) may be positioned inside the RV, in the middle cardiac vein 10 or in the coronary sinus 2. A second intra cardiac device
15 implemented as PM for stimulation of the left ventricle (LV) may additionally be positioned inside the LV from the aorta 18, in the lateral marginal veins 6, in the great cardiac vein 4 or in the coronary sinus 2. A third intra cardiac device implemented as a PM for stimulation of the
20 right atrium 22 may additionally be positioned inside the right atrium wall or right atrium appendage 12. An intra cardiac device implemented as a defibrillator may additionally be positioned inside the RV, the marginal veins, the great cardiac vein 4, the coronary sinus 2 or in
25 the middle cardiac vein 10. Each of these intra cardiac devices implemented as a units will communicate with each other. For instance during open chest surgery, the devices are attached to the heart surface directly, a technique that optimizes positioning.

30 An embodiment of the method according to the present invention is now described. The method provides for monitoring of the heart function by means of converting kinetic energy from the heart 1 to electrical energy and using information related to the electrical energy, e.g.

the amount of electricity produced over time, as an indicator of the heart function.

Initially access to the circulatory system is established. More precisely, one specific way is to first
5 establish access to the vein system by means of puncturing a large vein with a needle, wherein such veins might be the cubital arm vein, the cephalic vein, the internal jugular vein 78, the subclavian vein, the femoral vein 82 or any other vein large enough. Subsequently, a guide wire 76 is
10 inserted and an introducer sheath 78 with a hemostatic valve is placed over the wire. The guide wire 76 is then withdrawn. A diagnostic catheter 102 is inserted in the introducer sheath 78 to the location intended for positioning the device in the body. Preferably the catheter
15 is inserted in the vein system through the coronary sinus 2 and the great cardiac vein 4 into smaller branches along the lateral wall of the left ventricular wall 26, the lateral marginal branches. Other suitable positions in the vein system are for instance in the anterior inter-
20 ventricular vein on the front of the heart 1 or in the middle cardiac vein 10 behind the heart 1 between the left and the right ventricle. Once the diagnostic catheter 102 is in position an angiogram of the vein system is achieved using contrast dye. By interpreting the image from the
25 angiogram of the vein, the proper position for the device is determined. A guide wire 76 is now advanced to the selected position in the vein and beyond, whereupon the diagnostic catheter 102 is withdrawn, leaving the guide wire 76 in position. Over the guide wire 76 a guiding
30 catheter is advanced to the deployment site or adjacent. Now the delivery system 92 is advanced over the guide wire 76 but inside the guiding catheter to the desired site. If the device is kept inside the delivery system 92 by means of a restraining catheter, this is now retracted, thereby
35 exposing the device that is expanding inside the vein, e.g.

by a shape memory effect. This shape memory effect may for example be accomplished by polymers that present this feature, or with other suitable materials such as nitinol, which is a nickel-titanium alloy presenting this feature.

5 The device may thus fixate itself at the selected position, or in case the device has tines 56 the tines 56 will attach into the vein wall, keeping the device strongly fixated. In case the device has a screw 58 for fixation in the tissue, the delivery system 92 is rotated in the proper direction
10 until the screw 58 is solidly attached in the heart tissue. In case the fixation means is a stent 60 made of stainless steel, or another alloy, without shape memory, the fixation in the vessel is made by inflating a balloon inside the stent 60 for stent expansion. A pushing rod 96, a pushing
15 catheter 98, and an X-ray marker 100 are further elements used for certain of the herein described procedures.

If the device is to be deployed in a cavity like the RV 62, LV 64 or the right atrium 22, the same actions as above are executed until the guiding catheter and the
20 delivery system 92 is in position inside the cavity. The device is advanced and in case of a screw attachment the delivery system 92 is rotated in the proper direction until the device has a strong attachment in the heart tissue wall. In case the device has fixation tines 56 on the
25 outside a place between the papillary muscles 28 or between the trabecles of the heart muscle 30 is located where the tines 56 get a good attachment and then the device is released from the delivery system 92 by retracting the delivery catheter 94 from over the device.

30 Other fixation means are for instance eyelets 66 or a suture 68, as shown in Fig. 7f.

Once the intra cardiac energy and monitoring device 3 is in the proper position the movements of the heart 1 produce a certain amount of electricity in the device. This

is done by converting kinetic energy from the heart movement into electric energy, as described above.

The communication unit 7 of the intra cardiac device may transmit information to a receiver or an external
5 communication unit 104, e.g. outside of the body or in other implanted intra-cardiac devices. The information may be used for interpretation of the current or previous heart condition. The external communication unit 104 may comprise an antenna 106, which may be integrated inside a housing of
10 unit 104, and a display 108 for visualization of information.

The receiver outside of the body may be part of or connected to a mobile telephone or a fix-net telephone line for direct communication to a physician or a nurse for
15 monitoring purposes and for taking the right actions. The receiver might also be a part of or connected to intensive care monitors. The receiver might be a handheld unit and also have an algorithm and display suggesting to the patient directly the current status and which actions to
20 take.

A method according to another embodiment of the present invention is described for insertion of and establishing a electrical cardiac stimulator system, such as a pacemaker (PM) system, without leads or battery by
25 means of converting kinetic energy from the heart 1 to electricity and using the a certain amount of the electricity produced for stimulating the heart 1 electrically securing a safe heart rhythm. The same method is applied for positioning of electrical cardiac stimulator
30 devices implemented as defibrillation devices.

First access to the vein system is established by means of puncturing a large vein with a needle, such veins might be the cubital arm vein, the cephalic vein, the internal jugular vein 80, the subclavian vein, the femoral
35 vein 82 or any other vein large enough. A guide wire 76 is

then inserted and an introducer sheath 78 with a hemostatic valve is placed over the guide wire 76. Subsequently the guide wire 76 is withdrawn. Then a diagnostic catheter 102 is inserted to a location intended for positioning the device. For instance for LV pacing, the catheter may be inserted in the vein system through the coronary sinus 2 and the great cardiac vein 4 into smaller branches along the lateral wall of the left ventricular wall 26, the marginal branches. Other positions in the vein system would be in the anterior inter-ventricular vein on the front of the heart 1 or in the middle cardiac vein 10 behind the heart 1 between the left and the right ventricle.

Once the diagnostic catheter 102 is in position an angiogram of the vein system is achieved using contrast dye. By interpreting the image from the angiogram of the vein, the proper position for the device is decided. A guide wire 76 is now advanced to the selected position in the vein and beyond, whereupon the diagnostic catheter 102 is withdrawn, leaving the guide wire 76 in position. Over the guide wire 76 a guiding catheter is advanced to the deployment site or adjacent. Now the delivery system 92 is advanced over the guide wire 76 but inside the guiding catheter to the desired site. If the device is kept inside the delivery system 92 by means of a restraining catheter, this is now retracted, exposing the device that is expanding inside the vein and fixating itself there, or in case the device has tines 56 the tines 56 will attach to the vein wall, keeping the device strongly fixated. In case the device has a screw 58 for fixation in the tissue, the delivery system 92 is rotated in the proper direction until the screw 58 is solidly attached to the tissue. If the device has tines 56 for fixation they will engage the vein wall for secure anchoring. If the device is to be deployed in a cavity like the RV 62, LV 64, the right atrium 22 or the appendage of the right atrium 12, the same actions as

above are executed until the guiding catheter and the delivery system 92 is in position inside the cavity. The device is advanced and in case of a screw attachment the delivery system 92 is rotated in the proper direction until
5 the device has a strong attachment in the wall. In case the device has fixation tines 56 on the outside a place between the papillary muscles 28 or the muscular trabecles is located where the tines 56 get a good attachment and then the device is released from the delivery system 92 by
10 retracting the delivery catheter 94 from over the device. In case the electrical cardiac stimulator system comprises several electrical cardiac stimulator devices, the procedure described above is repeated for each of the device members of the system by means of repositioning the
15 guide catheter in the desired positions until all the devices in the system have been deployed. Once all electrical cardiac stimulator device, such as pacemaker, for example pace maker unit 70, and defibrillator devices, are in the proper positions the movements of the heart 1
20 will induce a certain amount of electricity in each of the devices. The devices are now able to communicate with the others. One of the devices, for instance an electrocardiogram detecting device may take the lead and run the operation of the system. The transmitting system of
25 each of the devices or the leading device only will send the information to a receiver or a communication unit 7 outside of the body for interpretation and setting mode of operation by means of transmitting back to the device(s). The receiver outside of the body may be part of or
30 connected to a mobile terminal or a fix-net telephone line for direct communication to a physician or a nurse for monitoring purposes and for taking the right actions. For instance most mobile terminals in the form of mobile telephones have an integrated Bluetooth wireless
35 communication port. Embodiments of the intra cardiac device

having a Bluetooth transmitter or transceiver may directly connect to such a mobile telephone according to a simple pairing routine matching the phone and the implanted device for communication. Once this link is established, data
5 communicated via the Bluetooth link may easily be forwarded to or received via the mobile networks connection of the mobile phone enabling a multitude of operations including maintenance actions or reprogramming of the implanted devices.

10 The external receiver communicating wirelessly with the implanted intra cardiac device may also communicate information via a distributed network, like the Internet, e.g. to a physician for examination.

The external receiver might also be a part of or
15 connected to intensive care monitors or telemetry systems. In the first case data from the intra cardiac devices may be displayed on the intensive care monitor. Often intensive care monitors are embedded in a network providing e.g. data storage, print outs etc., or even access to and from a
20 Hospital Information System.

Connecting intra cardiac devices of embodiments of the invention wirelessly to telemetry systems provides a number of advantages compared with today's telemetry systems. Especially the patient telemetry units do no
25 longer need ECG electrodes taped to the patient. Existing telemetry systems may be used with a simple transceiver outside the patient body managing communication both with the implanted intra cardiac device(s) and the fixed installed telemetry system. In this manner a convenient
30 continuous monitoring of a patient is provided right away from the end of implantation. This may contribute to cost saving in healthcare as patients that have undergone cardiac surgery may be directly submitted to non-critical care units.

The invention may be implemented in any suitable form, and the elements and components of an embodiment of the invention may be physically, functionally and logically implemented in any suitable way. Indeed, the functionality
5 may be implemented in a single unit, in a plurality of units or as part of other functional units. As such, the invention may be implemented in a single unit, or may be physically and functionally distributed between different units.

10 Although the present invention has been described above with reference to specific embodiments, it is not intended to be limited to the specific form set forth herein. Rather, the invention is limited only by the accompanying claims, and other embodiments than the
15 specific above are equally possible within the scope of these appended claims.

In the claims, the term "comprises/comprising" does not exclude the presence of other elements or steps. Furthermore, although individually listed, a plurality of
20 means, elements or method steps may be implemented. Additionally, although individual features may be included in different claims, these may possibly advantageously be combined, and the inclusion in different claims does not imply that a combination of features is not feasible and/or
25 advantageous. In addition, singular references do not exclude a plurality. The terms "a", "an", "first", "second" etc do not preclude a plurality. Reference signs in the claims are provided merely as a clarifying example and shall not be construed as limiting the scope of the claims
30 in any way.

CLAIMS

1. An intra cardiac device for heart function intervention,

5 c h a r a c e r i z e d b y

means for transforming kinetic energy from heart tissue movement into electrical energy in use, from which electrical energy information in respect of heart function is obtainable.

10

2. Intra cardiac device according to claim 1, wherein said means for transforming kinetic energy into electrical energy is a magnet (52), movable relative a coil (50).

15

3. Intra cardiac device according to claim 1, wherein said means for transforming kinetic energy into electrical energy is a rotatable pendulum (46), communicating with a magnet (52), rotatable relative a coil (50).

20

4. Intra cardiac device according to claim 1, wherein said means for transforming kinetic energy into electrical energy is a piezo-electric energy converter.

25

5. Intra cardiac device according to claim 1, further comprising an energy storage means, such as a capacitor, adapted to store said electrical energy for use by the intra-cardiac device.

30

6. Intra cardiac device according to claim 1, comprising a wireless transmitter or transceiver.

7. Intra cardiac device according to claim 1, comprising fixation means, for attachment of said device in

35

or at the heart (1), such as a stent (60), tines (56) or hooks, or a screw (58).

8. Intra cardiac device according to claim 1,
5 comprising elutionable steroids.

9. Intra cardiac device according to any preceding claim, wherein said intra cardiac device is configured to provide device function related data, such as
10 administrative data, programmed data like mode, cardiac stimulation pacing rate, defibrillation energy, power unit condition.

10. Intra cardiac device according to claim 1,
15 wherein said information is information in respect of heart function such as measured data like heart rate, heart movement amplitude, heart movement acceleration, electrical heart rate, electrical signal amplitude, or data related to previous cardiac events stored in the intra cardiac device.
20

11. Intra cardiac device according to any previous claim, wherein said device is a electrical cardiac stimulator device, such as an implantable pacemaker (70), cardioverter defibrillator or defibrillator.
25

12. Intra cardiac device according to claim 1 or 11, comprising at least one electronic circuit.

13. Intra cardiac device according to claim 11,
30 wherein said electronic circuit comprises pacing algorithms and/or defibrillating algorithms.

14. Intra cardiac device according to any previous claim, comprising a positive and a negative electrode.
35

15. Intra cardiac device according to claim 14,
wherein said positive and a negative electrode are
configured to obtain electrical heart signals.

5 16. Intra cardiac device according to claim 14 or 15,
wherein said electrical energy in use is stored in an
energy storage means, and wherein said energy storage means
is configured to provide energy stored therein for cardiac
stimulation via said positive and negative electrode when
10 electrical heart signals are not obtained via said positive
and negative electrode .

17. Intra cardiac device according to claim 14,
wherein said poles are made of good electrically conducting
15 material.

18. Intra cardiac device according to claim 14,
wherein said poles are made of copper or steel or a
polymer.
20

19. Intra cardiac device according to any of claims
14-18, wherein at least one of said poles is covered with
porous material.

25 20. Intra cardiac device according to claim 19,
wherein said porous material is activated carbon, sintered
platinum-iridium or sputtered titanium-nitride.

21. Intra cardiac device according to any preceding
30 claim, wherein said heart tissue is a heart muscle.

22. Intra cardiac device according to any preceding
claim, wherein said intra cardiac device is a leadless and
batteryless self-contained intra cardiac monitoring and/or
35 intra cardiac stimulating heart device capable of wireless

communication with other intra cardiac or extracorporeal devices.

23. A system, comprising at least one intra cardiac
5 device according to any of claims 1 to 22 and at least one receiver,

c h a r a c t e r i z e d b y

said at least one intra cardiac device comprising
means of communication, through which said at least one
10 device communicates with said at least one receiver
wirelessly.

24. System according to claim 23, wherein said at
least one receiver is an extracorporeal receiver located
15 outside a patients body in use of said system having said
at least one intra cardiac device implanted therein.

25. System according to claim 23, wherein said at
least one receiver is located in a mobile terminal such as
20 a mobile telephone, a fix-net telephone, an intensive care
monitor, a pacemaker (70), a defibrillator, an infusion
pump, or a transceiver of a telemetry system.

26. System according to claim 23, wherein said system
25 comprises a plurality of said intra cardiac devices and
wherein a first intra cardiac device of said plurality of
intra cardiac devices is configured to communicate with a
receiver located in a second intra cardiac device of said
plurality of intra cardiac devices.

30

27. System according to claim 23, wherein said intra
cardiac device is configured to communicate information in
respect of heart function derived from electrical energy
information originated during conversion from kinetic heart
35 movement energy to electrical energy to said receiver.

28. System according to any of claims 23-27, wherein
said means of communication is wireless communication
selected from the group comprising of wireless radio
transmission including Bluetooth or ZigBee, and ultrasound
communication, or combinations thereof.

29. A system according to any of claims 23-28,
further comprising a delivery system (92) for an intra
cardiac device, said delivery system (92) comprising
an intra cardiac device according to any of claims 1
to 22,
an introducer sheath (78),
a guide wire (76),
a diagnostic catheter (102), and
a delivery catheter (94).

30. A method of communication between a first intra
cardiac device according to any of claims 1 to 22 and a
receiver,
c h a r a c t e r i z e d i n
transforming kinetic energy from heart tissue
movement into electrical energy,
deriving information obtained from said transformed
electrical energy related to said heart movement, and
communicating said information to said receiver
wirelessly.

31. Method according to claim 30, further comprising
using said information to electrically instruct a second
intra cardiac device according to any of claims 1 to 22.

32. Method according to claim 30, further comprising
using said information in an external data assembly
equipment for monitoring said heart movement.

33. A method for monitoring heart function,
c h a r a c t e r i z e d i n
converting kinetic energy from heart tissue movement
5 to electrical energy,
using information related to said electrical energy
as an indicator of said heart function.

34. Method according to claim 33, further comprising
10 wirelessly communicating said information related to said
electrical energy to a receiver for interpretation.

35. Method according to claim 33, wherein said
receiver is located in an external data assembly equipment
15 outside of the patient body.

36. Method according to claim 35, wherein said
external data assembly equipment is a mobile terminal such
as a mobile telephone, or a fix-net telephone line, an
20 intensive care monitor, an infusion pump or a transceiver
of a telemetry system.

37. A method of treatment of heart blocks and
arrhythmias,
25 c h a r a c t e r i z e d i n
transforming kinetic energy from heart tissue
movement into electrical energy, and
deriving information obtained from said transformed
electrical energy related to said heart movement, by the
30 use of at least one intra cardiac device according to
claims 1 to 22; and
obtaining electrical heart signals from said at least
one intra cardiac device,

and stimulating the heart electrically by at least one intra cardiac device according to claims 1-22 with at least a part of said transformed electrical energy.

5 38. Method according to claim 37, wherein a first intra cardiac device communicates with at least a second intra cardiac device.

10 39. Method according to claim 38, wherein said first intra cardiac device acting as a master device and the at least second intra cardiac device acting as a slave device.

15 40. A method of monitoring congestive heart failure, characterized in transforming kinetic energy from heart tissue movement into electrical energy by the use of at least one intra cardiac device according to claims 1 to 22, deriving information obtained from said transformed electrical energy related to said heart movement, and
20 communicating said information to a receiver wirelessly.

25 41. A method for positioning a system of any of the intra cardiac devices according to claims 1 to 22, characterized by positioning said intra cardiac device in the right ventricle (RV), in the middle cardiac vein (10) or in the coronary sinus (2), positioning a second intra cardiac device inside the
30 LV from the aorta (18), in the lateral marginal veins (6), in the great cardiac vein (4) or in the coronary sinus (2), positioning a third intra cardiac device inside the wall of the right atrium (22) or right atrium appendage (12),

wherein each of these intra cardiac devices implemented as units in a system will communicate with each other.

5 42. The method according to claim 41, comprising positioning a fourth intra cardiac device, implemented as a defibrillator, inside the RV, the marginal veins, the great cardiac vein (4), the coronary sinus (2) or in the middle cardiac vein (10), which fourth intra cardiac device also
10 will communicate with said first, second, and/or third intra cardiac device.

 43. The method according to claim 41 or 42, wherein said intra cardiac devices are attached to the heart
15 surface directly for optimizing positioning.




Fig. 1

2/24




Fig. 2




Fig. 3

4/24




Fig. 4b




Fig. 4a

5/24




Fig. 5b




Fig. 5a

6/24




Fig. 5c

7/24




Fig. 6a

8/24




Fig. 6b

9/24




Fig. 7a

10/24




Fig. 7b

11/24




Fig. 7c

12/24




Fig. 7d

13/24




Fig. 7e

14/24




Fig. 7f

70




Fig. 8




Fig. 9

17/24




Fig. 10a

18/24




Fig. 10b

19/24




Fig. 10c




Fig. 11




Fig. 12

22/24




Fig. 13




Fig. 14a




Fig. 14b

24/24




Fig. 15

INTERNATIONAL SEARCH REPORT

International application No
PCT/EP2005/056700

A. CLASSIFICATION OF SUBJECT MATTER
INV. A61N1/365 A61N1/378

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
A61N A61B

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 2003/158584 A1 (CATES ADAM W [US] ET AL) 21 August 2003 (2003-08-21)	1,4,6,7, 9-18, 21-25, 27,28, 30, 32-36,40
Y	abstract; figures 1-20 paragraph [0011] - paragraph [0017] paragraph [0045] - paragraph [0152] ----- -/--	8,19,20, 26,29,31

☒ Further documents are listed in the continuation of Box C.

☒ See patent family annex.

* Special categories of cited documents :

A document defining the general state of the art which is not considered to be of particular relevance

E earlier document but published on or after the international filing date

L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O document referring to an oral disclosure, use, exhibition or other means

P document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

* & * document member of the same patent family

Date of the actual completion of the international search

28 September 2006

Date of mailing of the international search report

10/10/2006

Name and mailing address of the ISA/
European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Wetzig, Thomas

INTERNATIONAL SEARCH REPORT

International application No

PCT/EP2005/056700

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 2005/055061 A1 (HOLZER ASHER) 10 March 2005 (2005-03-10) abstract; figures 1-9 paragraph [0010] - paragraph [0043] paragraph [0058] - paragraph [0109] -----	1,2,5,7, 11-14, 17,18, 21,33
X	US 3 835 864 A (RASOR N,US ET AL) 17 September 1974 (1974-09-17) abstract; figures 1,5,10,11 column 1, line 54 - column 3, line 22 column 3, line 55 - column 10, line 43 -----	1-3,33
Y	-----	29
X	US 4 798 206 A (MADDISON ET AL) 17 January 1989 (1989-01-17) abstract; figures 1-16 column 2, line 17 - column 3, line 29 column 4, line 5 - column 8, line 32 -----	1,4,10, 33
X	US 5 431 694 A (SNAPER ET AL) 11 July 1995 (1995-07-11) the whole document -----	1,4,5,33
Y	US 5 103 837 A (WEIDLICH ET AL) 14 April 1992 (1992-04-14) abstract column 1, line 4 - line 7 column 3, line 46 - line 51 -----	8,19,20
Y	EP 1 541 191 A (JAPAN AS REPRESENTED BY PRESIDENT OF NATIONAL CARDIOVASCULAR CENTER) 15 June 2005 (2005-06-15) abstract; figures 9,10 -----	26,31

INTERNATIONAL SEARCH REPORT

International application No.
PCT/EP2005/056700

Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 37-39, 41-43
because they relate to subject matter not required to be searched by this Authority, namely:
Rule 39.1(iv) PCT - Method for treatment of the human or animal body by therapy (claims 37-39) Rule 39.1(iv) PCT - Method for treatment of the human or animal body by surgery (claims 41-43)
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/EP2005/056700

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 2003158584 A1	21-08-2003	NONE	
US 2005055061 A1	10-03-2005	NONE	
US 3835864 A	17-09-1974	CA 1003904 A1 DE 2147308 A1 FR 2107826 A5 GB 1371034 A GB 1371033 A IT 942190 B NL 7112915 A SE 7410205 A	18-01-1977 23-03-1972 12-05-1972 23-10-1974 23-10-1974 20-03-1973 23-03-1972 09-08-1974
US 4798206 A	17-01-1989	NONE	
US 5431694 A	11-07-1995	NONE	
US 5103837 A	14-04-1992	EP 0388480 A1	26-09-1990
EP 1541191 A	15-06-2005	AU 2002323811 A1 AU 2003252379 A1 CN 1674958 A WO 2004012810 A1 WO 2004012811 A1	23-02-2004 23-02-2004 28-09-2005 12-02-2004 12-02-2004